Kerasal NeuroCream
Natural health product licensed in Canada
- Licence holder
- Advantice Health LLC
- NPN or DIN-HM
- 80052768
- Status
- Active licence
- Licence date
- 29 July 2014
- Revision date
- Not provided
- Form
- Crème
- Route of administration
- Topique
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| d-camphre Source : d-Camphre | 5.65 % (p/p) |
| (E)-8-Méthyl-N-vanillyl-6-nonenamide Source : Capsaïcine | 0.075 % (p/p) |
Non-medicinal ingredients
Urée, Sesquistéarate de méthyl glucose, L-arginine, Carbomère de potassium, Nitrate de thiamine, Monostéarate de glycéryle, Huile essentielle d'arbre à thé, Diazolidinyl urée, Methyl gluceth-20, Pétrolatum, Polymère croisé d'acrylates/acrylate d'alkyle en C10 à 30, Hypromellose, EDTA de sodium, Lanoline acétylée, Lanoline hydroxylée, Glycérine, Poly(sorbate) 20, Sulfate de glucosamine, Vitamine B12, Diméthicone, Stéarate de diméthiconol, Butylcarbamate d'iodopropynyle, Extrait de feuilles d'Aloe barbadensis, DL-Panthénol, Huile Essentielle d'Eucalyptus, Eau purifiée, Acétate de dl-alpha tocophéryle, Benzoate d'alkyle en C12 à 15
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 12 years | 1 Crème | minimum: 3 days ; maximum: 4 days |
Uses authorised in Canada
Temporarily relieves aches and pains of muscles and joints associated with one or more of the following: Strains and sprains (involving muscles, tendons, and/or ligaments), and arthritis. Capsaicin: Counterirritant. Camphor: Topical Analgesic/Counterirritant.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a Poison Control Center immediately. If symptoms persist and/or worsen after 7 days or re-occur within a few days, discontinue use and consult a health care practitioner. If you are pregnant or breastfeeding, consult a health care practitioner prior to use. Rashes and/or burning discomfort have been known to occur; in which case, discontinue use. Hypersensitivity has been known to occur; in which case, discontinue use. Headache, erythema, redness, and burning discomfort have been known to occur; in which case, discontinue use. Ask a health care practitioner before use if you have sensitive skin When using this product: Do not expose treated area to direct sunlight or heat. A temporary burning sensation may occur, but will usually disappear after a few days of use.
Source
Official Health Canada record, licence 80052768
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.